Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Matinas BioPharma stock

Learn how to easily invest in Matinas BioPharma stock.

Matinas BioPharma Holdings Inc is a biotechnology business based in the US. Matinas BioPharma shares (MTNB) are listed on the NYSE MKT and all prices are listed in US Dollars. Matinas BioPharma employs 31 staff and has a trailing 12-month revenue of around $1.1 million.

How to buy shares in Matinas BioPharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MTNB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Matinas BioPharma stock price (NYSE MKT: MTNB)

Use our graph to track the performance of MTNB stocks over time.

Matinas BioPharma shares at a glance

Information last updated 2022-09-25.
Latest market close$0.63
52-week range$0.49 - $1.61
50-day moving average $0.79
200-day moving average $0.79
Wall St. target price$2.75
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.12

Buy Matinas BioPharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 8 of 8
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Matinas BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Matinas BioPharma price performance over time

Historical closes compared with the close of $0.629 from 2022-09-23

1 week (2022-09-19) -7.50%
1 month (2022-08-26) -13.36%
3 months (2022-06-27) -22.35%
6 months (2022-03-25) -30.88%
1 year (2021-09-27) -57.50%
2 years (2020-09-25) -20.48%
3 years (2019-09-27) 0.63
5 years (2017-09-26) 1.26

Matinas BioPharma financials

Revenue TTM $1.1 million
Gross profit TTM $-14,549,950
Return on assets TTM -27.82%
Return on equity TTM -48.11%
Profit margin 0%
Book value $0.20
Market capitalisation $136.3 million

TTM: trailing 12 months

Matinas BioPharma share dividends

We're not expecting Matinas BioPharma to pay a dividend over the next 12 months.

Matinas BioPharma share price volatility

Over the last 12 months, Matinas BioPharma's shares have ranged in value from as little as $0.49 up to $1.61. A popular way to gauge a stock's volatility is its "beta".

MTNB.US volatility(beta: 2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Matinas BioPharma's is 1.9996. This would suggest that Matinas BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Matinas BioPharma overview

Matinas BioPharma Holdings, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections.

Frequently asked questions

What percentage of Matinas BioPharma is owned by insiders or institutions?
Currently 3.806% of Matinas BioPharma shares are held by insiders and 12.601% by institutions.
How many people work for Matinas BioPharma?
Latest data suggests 31 work at Matinas BioPharma.
When does the fiscal year end for Matinas BioPharma?
Matinas BioPharma's fiscal year ends in December.
Where is Matinas BioPharma based?
Matinas BioPharma's address is: 1545 Route 206 South, Bedminster, NJ, United States, 07921
What is Matinas BioPharma's ISIN number?
Matinas BioPharma's international securities identification number is: US5768101058
What is Matinas BioPharma's CUSIP number?
Matinas BioPharma's Committee on Uniform Securities Identification Procedures number is: 576810105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site